Solbec soars 70 per cent on cancer drug result

By Staff Writers
Tuesday, 23 November, 2004

Shares in Solbec Pharmaceuticals (ASX:SBP) jumped almost 70 per cent to $0.21 today after preliminary results from a study conducted by the Tumour Immunology Group at the University of Western Australia indicated that the company's cancer drug, Coramsine, was effective in treating and preventing mesothelioma in a mouse model of the cancer.

Mice treated with Coramsine in combination with the immune-triggering compound CpG -- a synthetic DNA fragment containing cytosine and guanine -- showed total remission of the mesothelioma. The therapy also seemed to confer lasting immunity against mesothelioma, as attempts to cause tumour formation in a treated, 'cured' mouse failed.

Coramsine is a mixture of two alkaloids from the prickly weed Solanum linneaum, also known as devil's apple.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd